LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 256 of 520
Next
>>
>
6376 to 6400 of 12982 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Normalized Growth Rate Inhibition Value
BT-20	AZD8055	10	uM	LJP6	3	A07	72	hr	1334	1020	3921	0.2601	-0.1588
BT-20	Sorafenib	0.04	uM	LJP6	1	B12	72	hr	1334	3930	3955	0.9935	0.9917
BT-20	Sorafenib	0.04	uM	LJP6	2	B12	72	hr	1334	3786	3899	0.9710	0.9623
BT-20	Sorafenib	0.04	uM	LJP6	3	B12	72	hr	1334	3614	3921	0.9216	0.8977
BT-20	Sorafenib	0.12	uM	LJP6	1	B11	72	hr	1334	3731	3955	0.9432	0.9267
BT-20	Sorafenib	0.12	uM	LJP6	2	B11	72	hr	1334	3757	3899	0.9636	0.9526
BT-20	Sorafenib	0.12	uM	LJP6	3	B11	72	hr	1334	3806	3921	0.9706	0.9620
BT-20	Sorafenib	0.37	uM	LJP6	1	B10	72	hr	1334	3571	3955	0.9027	0.8736
BT-20	Sorafenib	0.37	uM	LJP6	2	B10	72	hr	1334	3684	3899	0.9448	0.9279
BT-20	Sorafenib	0.37	uM	LJP6	3	B10	72	hr	1334	3548	3921	0.9048	0.8754
BT-20	Sorafenib	1.11	uM	LJP6	1	B09	72	hr	1334	3510	3955	0.8873	0.8531
BT-20	Sorafenib	1.11	uM	LJP6	2	B09	72	hr	1334	3563	3899	0.9138	0.8868
BT-20	Sorafenib	1.11	uM	LJP6	3	B09	72	hr	1334	3657	3921	0.9326	0.9122
BT-20	Sorafenib	3.33	uM	LJP6	1	B08	72	hr	1334	3617	3955	0.9144	0.8890
BT-20	Sorafenib	3.33	uM	LJP6	2	B08	72	hr	1334	3602	3899	0.9238	0.9001
BT-20	Sorafenib	3.33	uM	LJP6	3	B08	72	hr	1334	3351	3921	0.8546	0.8077
BT-20	Sorafenib	10	uM	LJP6	1	B07	72	hr	1334	3092	3955	0.7816	0.7091
BT-20	Sorafenib	10	uM	LJP6	2	B07	72	hr	1334	3279	3899	0.8410	0.7881
BT-20	Sorafenib	10	uM	LJP6	3	B07	72	hr	1334	3685	3921	0.9397	0.9216
BT-20	CP466722	0.04	uM	LJP5	1	I12	72	hr	1334	4070	3930	1.0354	1.0452
BT-20	CP466722	0.04	uM	LJP5	2	I12	72	hr	1334	4312	4051	1.0644	1.0795
BT-20	CP466722	0.04	uM	LJP5	3	I12	72	hr	1334	4339	4117	1.0538	1.0655
BT-20	CP466722	0.12	uM	LJP5	1	I11	72	hr	1334	3953	3930	1.0057	1.0072
BT-20	CP466722	0.12	uM	LJP5	2	I11	72	hr	1334	4359	4051	1.0760	1.0936
BT-20	CP466722	0.12	uM	LJP5	3	I11	72	hr	1334	4203	4117	1.0207	1.0254

|<
<<
Previous
Page 256 of 520
Next
>>
>
6376 to 6400 of 12982 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)